• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    KemPharm Announces Appointment of Christopher Posner as New Independent Director

    11/29/22 7:30:00 AM ET
    $CARA
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CARA alert in real time by email

    24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors

    CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors.

    Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company. He brings more than 20 years of global pharmaceutical experience to KemPharm, including expertise in preparing and executing commercial product launches.

    "Chris is a tremendous addition to KemPharm's Board as we continue to drive our strategic transformation and intensify our clinical, regulatory and pre-commercial activities in anticipation of multiple value-building opportunities from our arimoclomol and KP1077 programs," said Richard W. Pascoe, Executive Chairman of KemPharm. "In particular, we look forward to benefiting from Chris' expertise in building commercial organizations and managing product launches, which will prove beneficial to KemPharm and our goal of building a rare disease sales organization focused on bringing novel treatments to patients suffering from rare CNS, neurological and lysosomal storage disorder diseases."

    Mr. Posner's career is highlighted by broad experience in commercial and marketing operations and product management at both large and specialty pharmaceutical companies, where he has focused on commercializing novel therapies addressing life altering conditions, including XELJANZ® and ENBREL®. Prior to joining Cara Therapeutics, Mr. Posner was President and Chief Executive Officer of LEO Pharma, Inc., the U.S. subsidiary of LEO Pharma A/S. Prior to joining LEO, Mr. Posner was the Head of Worldwide Commercial Operations at R-Pharma-US, LLC, a specialty pharmaceutical company focused on oncology and chronic immune disorders. Previously, Mr. Posner held roles of increasing responsibility in senior management positions in commercial and marketing operations at Bristol-Myers Squibb Company, Pfizer Inc., Wyeth Pharmaceuticals, Inc., and Endo International plc. Mr. Posner holds an M.B.A. from the Fuqua School of Business at Duke University and a B.A. in economics from Villanova University.

    "I welcome the opportunity to join KemPharm at a very exciting period for the company," said Mr. Posner. "KemPharm anticipates multiple value drivers over the next 12 months, including the initiation of a Phase 2 clinical trial for KP1077 in idiopathic hypersomnia prior to the end of the year and the resubmission of an NDA for arimoclomol as early as the third quarter of 2023. I am eager to work with the Board and management to capitalize on these and other opportunities to create long-term value for all stakeholders."

    About KemPharm:

    KemPharm is a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare CNS and neurodegenerative diseases, lysosomal storage disorders and related treatment areas. KemPharm has a diverse product portfolio, combining a clinical-stage development pipeline with NDA-stage and commercial assets. The pipeline includes arimoclomol, an orally-delivered, first-in-class investigational product candidate for Niemann-Pick disease type C (NPC), and KP1077, which the Company is developing as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. In addition, the U.S. Food and Drug Administration (FDA) has approved AZSTARYS®, a once-daily treatment for ADHD in patients age six years and older containing KemPharm's prodrug, serdexmethylphenidate (SDX), which is being commercialized by Corium, Inc. in the U.S. The FDA has also approved APADAZ®, an immediate-release combination product containing benzhydrocodone, KemPharm's prodrug of hydrocodone, and acetaminophen, which is being commercialized by KVK-Tech, Inc. in the U.S. For more information on KemPharm and its pipeline of product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.

    Early access programs are made available by KemPharm, Inc. and its affiliates, and are subject to the Company's Early Access Program (EAP) policy as published on its website at www.kempharm.com. Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the discretion of the treating physician.

    Caution Concerning Forward Looking Statements:

    This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation and which can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue," "could," "intend," "target," "predict," or the negative versions of those words or other comparable words or expressions, although not all forward-looking statements contain these identifying words or expressions. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements include statements regarding the promise and potential impact of our preclinical or clinical trial data, including without limitation the initiation, timing and results of any clinical trials or readouts, the timing or results of any Investigational New Drug applications and New Drug Application (NDA) submissions, including the resubmission of the NDA for arimoclomol, the potential uses or benefits of arimoclomol, KP1077, SDX, or any other product candidates for any specific disease indication or at any dosage, the potential benefits of any of KemPharm's product candidates, and our strategic and product development objectives. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of KemPharm's Annual Report on Form 10-K for the year ended December 31, 2021, as updated by KemPharm's Quarterly Report on Form 10-Q for the three months ended September 30, 2022, and KemPharm's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    KemPharm Contacts:

    Tiberend Strategic Advisors, Inc.

    Jason Rando/Daniel Kontoh-Boateng

    [email protected]

    [email protected]



    Primary Logo

    Get the next $CARA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CARA
    $KMPH

    CompanyDatePrice TargetRatingAnalyst
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$6.00 → $1.00Buy → Hold
    Stifel
    Cara Therapeutics Inc.
    $CARA
    6/13/2024$10.00 → $1.00Buy → Hold
    Canaccord Genuity
    Cara Therapeutics Inc.
    $CARA
    6/13/2024Buy → Hold
    Needham
    Cara Therapeutics Inc.
    $CARA
    6/13/2024Buy → Neutral
    H.C. Wainwright
    Cara Therapeutics Inc.
    $CARA
    3/8/2023$13.00 → $6.00Neutral → Underperform
    BofA Securities
    KemPharm Inc.
    $KMPH
    11/17/2022$20.00Overweight
    Cantor Fitzgerald
    KemPharm Inc.
    $KMPH
    9/15/2022$20.00Buy
    Canaccord Genuity
    Cara Therapeutics Inc.
    $CARA
    3/8/2022$17.00 → $20.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $CARA
    $KMPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

      STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that its Board of Directors (the "Board") has approved a 1-for-3 reverse stock split of its outstanding shares of common stock. Cara's common stock is expected to begin trading on a reverse stock split-adjusted basis at the opening of the market on Wednesday, April 16, 2025 under the new name "Tvardi Therapeutics, Inc." and under the new symbol "TVRD" following the anticipated closing of the merger (the "Merger") with Tvard Therapeutics, Inc. ("Tvardi"), with a new CUSIP number 140755 307. The reverse stock split was approved by Cara's stockholders at Cara's special

      4/14/25 11:50:29 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

      STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) (the "Company"), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Tuesday, December 31, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "CARA" with the new CUSIP number, 1

      12/27/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

      Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos

      12/18/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    $KMPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

      Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

      8/24/21 12:36:58 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    $KMPH
    Financials

    Live finance-specific insights

    See more

    $CARA
    $KMPH
    Leadership Updates

    Live Leadership Updates

    See more

    $CARA
    $KMPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

      Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi's existing cash and Cara's anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utilizing its STAT3 inhibitor, TTI-101, including its lead program in idiopathic pulmonary fibrosis and its program in hepatocellular carcinoma Companies to hos

      12/18/24 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

      –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operatio

      3/4/24 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

      STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under "Events & Presentations" in the Investors section of the Company's website at www.CaraTherapeutics.com. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical co

      2/12/24 4:01:00 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

      STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous public boards. "We are pleased to welcome Helen to the Cara board," said Christopher Posner, President, Chief Executive Officer and Director of Cara Therapeutics. "We look forward to leveraging her

      8/3/23 7:00:00 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

      Matthew R. Plooster named Chairman of the Board of DirectorsRichard W. Pascoe appointed Chief Executive OfficerTravis C. Mickle, Ph.D. transitions to PresidentJoshua Schafer appointed Chief Commercial Officer and Executive Vice President of Business Development CELEBRATION, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS), neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced changes to its Board of Directors (Board) and executive leadership team as part of the Company's ongoing b

      1/9/23 6:30:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Announces Appointment of Christopher Posner as New Independent Director

      24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.

      11/29/22 7:30:00 AM ET
      $CARA
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Cara Therapeutics Inc.

      SC 13D - Cara Therapeutics, Inc. (0001346830) (Subject)

      10/30/24 4:21:50 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KemPharm Inc.

      SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

      2/14/24 4:51:40 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cara Therapeutics Inc. (Amendment)

      SC 13G/A - Cara Therapeutics, Inc. (0001346830) (Subject)

      2/13/24 6:50:36 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    $KMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:20 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, Research & Development Larson Jeffrey Leroy

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:32 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul

      4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)

      4/21/25 5:15:30 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CARA
    $KMPH
    SEC Filings

    See more

    $CARA
    $KMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cara Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Disclosure, Other Events

      8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)

      4/15/25 4:06:29 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cara Therapeutics, Inc. (0001346830) (Filer)

      4/11/25 4:16:03 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Cara Therapeutics, Inc. (0001346830) (Filer)

      4/1/25 4:30:32 PM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $6.00 previously

      6/13/24 7:05:24 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $10.00 previously

      6/13/24 7:05:04 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics downgraded by Needham

      Needham downgraded Cara Therapeutics from Buy to Hold

      6/13/24 7:04:33 AM ET
      $CARA
      Biotechnology: Pharmaceutical Preparations
      Health Care